The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Locatim exceed the risks for the treatment of calves less than 12 hours of age to reduce mortality caused by enterotoxicosis associated with E. coli F5 (K99) adhesin during the first days of life as a supplement to colostrum from the dam, and recommended that Locatim be given a marketing authorisation.